NO301216B1 - Nikotinplaster - Google Patents

Nikotinplaster Download PDF

Info

Publication number: NO301216B1
Authority: NO; Norway
Prior art keywords: nicotine; patch; skin; membrane; hours
Prior art date: 1988-10-28

Application number

NO893570A

Other languages

English (en)

Norwegian (no)

Other versions

NO893570D0 (no

NO893570L (no

Inventor

Richard W Baker

Frank Kochinke

Carl Huang

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-28

Filing date

1989-09-05

Publication date

1997-09-29

1989-09-05 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

1989-09-05 Publication of NO893570D0 publication Critical patent/NO893570D0/no

1990-04-30 Publication of NO893570L publication Critical patent/NO893570L/no

1997-09-29 Publication of NO301216B1 publication Critical patent/NO301216B1/no

Links

SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 292
229960002715 nicotine Drugs 0.000 title claims abstract description 292
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 292
239000012528 membrane Substances 0.000 claims abstract description 72
230000004907 flux Effects 0.000 claims abstract description 6
239000000463 material Substances 0.000 claims description 51
239000000853 adhesive Substances 0.000 claims description 28
230000001070 adhesive effect Effects 0.000 claims description 28
229920000642 polymer Polymers 0.000 claims description 28
-1 polyethylene Polymers 0.000 claims description 15
239000004698 Polyethylene Substances 0.000 claims description 12
229920000573 polyethylene Polymers 0.000 claims description 12
238000009792 diffusion process Methods 0.000 claims description 10
229920002635 polyurethane Polymers 0.000 claims description 10
239000004814 polyurethane Substances 0.000 claims description 10
239000002390 adhesive tape Substances 0.000 claims description 5
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 4
230000037317 transdermal delivery Effects 0.000 claims description 4
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
239000004952 Polyamide Substances 0.000 claims description 2
229920006226 ethylene-acrylic acid Polymers 0.000 claims description 2
229920002647 polyamide Polymers 0.000 claims description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
239000006185 dispersion Substances 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 abstract description 10
230000005586 smoking cessation Effects 0.000 abstract description 7
230000009885 systemic effect Effects 0.000 abstract description 3
239000010410 layer Substances 0.000 description 41
239000003814 drug Substances 0.000 description 38
229940079593 drug Drugs 0.000 description 37
239000011159 matrix material Substances 0.000 description 24
238000000034 method Methods 0.000 description 22
239000010408 film Substances 0.000 description 21
239000000243 solution Substances 0.000 description 20
230000000694 effects Effects 0.000 description 17
230000008901 benefit Effects 0.000 description 13
238000000338 in vitro Methods 0.000 description 12
231100000245 skin permeability Toxicity 0.000 description 12
239000000203 mixture Substances 0.000 description 11
230000035699 permeability Effects 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
239000007788 liquid Substances 0.000 description 10
229920000728 polyester Polymers 0.000 description 10
239000012790 adhesive layer Substances 0.000 description 9
206010040880 Skin irritation Diseases 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
238000013270 controlled release Methods 0.000 description 8
231100000475 skin irritation Toxicity 0.000 description 8
230000036556 skin irritation Effects 0.000 description 8
230000000391 smoking effect Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
235000019504 cigarettes Nutrition 0.000 description 7
229920005597 polymer membrane Polymers 0.000 description 7
238000007789 sealing Methods 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
229920001903 high density polyethylene Polymers 0.000 description 6
239000004700 high-density polyethylene Substances 0.000 description 6
239000011505 plaster Substances 0.000 description 6
238000003860 storage Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000004677 Nylon Substances 0.000 description 5
239000004721 Polyphenylene oxide Substances 0.000 description 5
229920001778 nylon Polymers 0.000 description 5
229920000570 polyether Polymers 0.000 description 5
239000011148 porous material Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
229920003345 Elvax® Polymers 0.000 description 4
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
239000000006 Nitroglycerin Substances 0.000 description 4
238000005266 casting Methods 0.000 description 4
238000013461 design Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
229960003711 glyceryl trinitrate Drugs 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
229920001179 medium density polyethylene Polymers 0.000 description 4
239000004701 medium-density polyethylene Substances 0.000 description 4
239000002504 physiological saline solution Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 3
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
230000037058 blood plasma level Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229940112822 chewing gum Drugs 0.000 description 3
235000015218 chewing gum Nutrition 0.000 description 3
239000002131 composite material Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000011888 foil Substances 0.000 description 3
239000003292 glue Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
231100000636 lethal dose Toxicity 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000012982 microporous membrane Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
231100000816 toxic dose Toxicity 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
206010057852 Nicotine dependence Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
208000025569 Tobacco Use disease Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000000622 irritating effect Effects 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000037368 penetrate the skin Effects 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
229960002646 scopolamine Drugs 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
229920001169 thermoplastic Polymers 0.000 description 2
239000004416 thermosoftening plastic Substances 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229940100640 transdermal system Drugs 0.000 description 2
231100000925 very toxic Toxicity 0.000 description 2
208000032529 Accidental overdose Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
229920002799 BoPET Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
229920010930 Hytrel® 5556 Polymers 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
239000005041 Mylar™ Substances 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229920001328 Polyvinylidene chloride Polymers 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
206010059516 Skin toxicity Diseases 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical class CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229920000891 common polymer Polymers 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000000806 elastomer Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
QHZOMAXECYYXGP-UHFFFAOYSA-N ethene;prop-2-enoic acid Chemical compound C=C.OC(=O)C=C QHZOMAXECYYXGP-UHFFFAOYSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000026781 habituation Effects 0.000 description 1
235000019589 hardness Nutrition 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000012567 medical material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000012229 microporous material Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920001896 polybutyrate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000005033 polyvinylidene chloride Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
239000004945 silicone rubber Substances 0.000 description 1
231100000438 skin toxicity Toxicity 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229920002725 thermoplastic elastomer Polymers 0.000 description 1
239000010409 thin film Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

NO893570A 1988-10-28 1989-09-05 Nikotinplaster NO301216B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/264,397 US4943435A (en)	1987-10-05	1988-10-28	Prolonged activity nicotine patch

Publications (3)

Publication Number	Publication Date
NO893570D0 NO893570D0 (no)	1989-09-05
NO893570L NO893570L (no)	1990-04-30
NO301216B1 true NO301216B1 (no)	1997-09-29

Family

ID=23005890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO893570A NO301216B1 (no)	1988-10-28	1989-09-05	Nikotinplaster

Country Status (13)

Country	Link
US (1)	US4943435A (fr)
EP (2)	EP0916339B1 (fr)
JP (1)	JP3359630B2 (fr)
AT (2)	ATE292968T1 (fr)
AU (1)	AU635714B2 (fr)
CA (1)	CA1338009C (fr)
DE (2)	DE68928952T2 (fr)
DK (1)	DK175328B1 (fr)
ES (2)	ES2129387T3 (fr)
GR (1)	GR3030041T3 (fr)
MX (1)	MX165947B (fr)
NO (1)	NO301216B1 (fr)
NZ (1)	NZ230554A (fr)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6139868A (en) *	1986-08-28	2000-10-31	Lts Lohmann Therapie-Systeme Gmbh & Co. Kg	Transdermal therapeutic system, its use and production process
AU622162B2 (en) *	1988-04-22	1992-04-02	Ciba-Geigy Ag	Transdermal monolith systems
US5004610A (en) *	1988-06-14	1991-04-02	Alza Corporation	Subsaturated nicotine transdermal therapeutic system
AU682813B2 (en) *	1988-06-14	1997-10-23	Alza Corporation	Subsaturated transdermal delivery device
US5077104A (en) *	1989-12-21	1991-12-31	Alza Corporation	Nicotine packaging materials
US5455043A (en) *	1990-06-13	1995-10-03	Fischel-Ghodsian; Fariba	Device for controlled release of vaporous medications through nasal route
US5071704A (en) *	1990-06-13	1991-12-10	Fischel Ghodsian Fariba	Device for controlled release of vapors and scents
US5512292A (en) *	1990-10-29	1996-04-30	Alza Corporation	Transdermal contraceptive formulations methods and devices
US5403595A (en) *	1991-05-07	1995-04-04	Dynagen, Inc.	Controlled, sustained release delivery system for smoking cessation
US5402777A (en) *	1991-06-28	1995-04-04	Alza Corporation	Methods and devices for facilitated non-invasive oxygen monitoring
PT100973A (pt) *	1991-10-18	1994-06-30	Alza Corp	Dispositivo e composicoes farmaceuticas para a administracao de melatonina por via transdermica
ATE155045T1 (de) *	1991-11-13	1997-07-15	Elan Corp Plc	Vorrichtung zur verabreichung von heilmitteln
CA2075517C (fr) *	1992-04-01	1997-03-11	John Wick	Piece transdermique incorporant une pellicule de polymeres incorporee a l'aide d'un agent actif
US6010715A (en) *	1992-04-01	2000-01-04	Bertek, Inc.	Transdermal patch incorporating a polymer film incorporated with an active agent
US5780051A (en) *	1992-04-02	1998-07-14	Dynagen, Inc.	Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5900250A (en) *	1992-05-13	1999-05-04	Alza Corporation	Monoglyceride/lactate ester permeation enhancer for oxybutnin
JP3786684B2 (ja) *	1992-05-13	2006-06-14	アルザ・コーポレーション	オキシブチニンの経皮投与
US5883115A (en) *	1992-11-09	1999-03-16	Pharmetrix Division Technical Chemicals & Products, Inc.	Transdermal delivery of the eutomer of a chiral drug
US5762952A (en) *	1993-04-27	1998-06-09	Hercon Laboratories Corporation	Transdermal delivery of active drugs
US6602892B1 (en)	1993-06-10	2003-08-05	David P. L. Sachs	Methods for nicotine replacement dosage determination
US5451407A (en) *	1993-06-21	1995-09-19	Alza Corporation	Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
EP0705097B2 (fr) *	1993-06-25	2004-01-14	Alza Corporation	Incorporation d'un amide poly-n-vinylique a un systeme transdermique
AU7323794A (en) *	1993-07-09	1995-02-06	Cygnus Therapeutic Systems	Method and device for providing nicotine replacement therapy transdermally/transbuccally
US5362496A (en) *	1993-08-04	1994-11-08	Pharmetrix Corporation	Method and therapeutic system for smoking cessation
DE4332094C2 (de) *	1993-09-22	1995-09-07	Lohmann Therapie Syst Lts	Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung
EP0721349A1 (fr) *	1993-09-29	1996-07-17	Alza Corporation	Renforcateur de permeation de l'oxybutine a base de monoglyceride/lactate
AU676430B2 (en) *	1994-03-07	1997-03-06	Theratech, Inc.	Drug-containing adhesive composite transdermal delivery device
US5547681A (en) *	1994-07-14	1996-08-20	Union Carbide Chemicals & Plastics Technology Corporation	Dermal patch
US6572879B1 (en) *	1995-06-07	2003-06-03	Alza Corporation	Formulations for transdermal delivery of pergolide
US6093419A (en) *	1995-06-07	2000-07-25	Lectec Corporation	Compliance verification method and device in compulsory drug administration
US5785991A (en) *	1995-06-07	1998-07-28	Alza Corporation	Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5716635A (en) *	1995-07-19	1998-02-10	M. E. Cody Products, Inc.	Plantago major transdermal patch for use in treating a tobacco or nicotine habit
US5840327A (en) *	1995-08-21	1998-11-24	Alza Corporation	Transdermal drug delivery device having enhanced adhesion
US6512010B1 (en)	1996-07-15	2003-01-28	Alza Corporation	Formulations for the administration of fluoxetine
AUPO108596A0 (en) *	1996-07-18	1996-08-08	Collier, Gregory	Treatment of obesity
AU4990797A (en) *	1996-10-24	1998-05-15	Alza Corporation	Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DE19650329A1 (de) *	1996-12-04	1998-06-10	Hexal Ag	Flächiges selbsthaftendes Wirkstoffpflaster
DE19705138A1 (de) *	1997-02-11	1998-08-13	Lohmann Therapie Syst Lts	Dehnbares transdermales therapeutisches System
US6203817B1 (en)	1997-02-19	2001-03-20	Alza Corporation	Reduction of skin reactions caused by transdermal drug delivery
US6113940A (en) *	1997-03-03	2000-09-05	Brooke; Lawrence L.	Cannabinoid patch and method for cannabis transdermal delivery
US6660295B2 (en)	1997-09-30	2003-12-09	Alza Corporation	Transdermal drug delivery device package with improved drug stability
WO1999032153A1 (fr)	1997-12-22	1999-07-01	Alza Corporation	Compositions de monoglyceride et de palmitate d'ethyle stimulatrices de permeation
US6063401A (en) *	1998-05-06	2000-05-16	M.E. Cody Products, Inc.	Plantago major and hypericum perforatum compound for use in treating a tobacco or nicotine habit
MY122454A (en)	1998-06-05	2006-04-29	Upjohn Co	Use of oxazolidinones for the preparation of a medicament for transdermal delivery
US6045825A (en)	1998-06-17	2000-04-04	M. E. Cody Products, Inc.	Plantago major and Piper methysticum compound for use in treating a tobacco or nicotine habit
US6699497B1 (en)	1998-07-24	2004-03-02	Alza Corporation	Formulations for the transdermal administration of fenoldopam
US6348210B1 (en)	1998-11-13	2002-02-19	Alza Corporation	Methods for transdermal drug administration
HUP0104728A3 (en) *	1998-12-18	2006-07-28	Alza Corp Mountain View	Transparent transdermal nicotine delivery device
US6270781B1 (en)	1999-01-08	2001-08-07	Maxim Pharmaceuticals, Inc.	Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6242473B1 (en)	1999-01-08	2001-06-05	Maxim Pharmaceuticals, Inc.	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU778081B2 (en) *	1999-03-25	2004-11-11	Tepha, Inc.	Medical devices and applications of polyhydroxyalkanoate polymers
AU3932600A (en) *	1999-04-01	2000-10-23	Alza Corporation	Transdermal drug delivery devices comprising a polyurethane drug reservoir
US6248760B1 (en) *	1999-04-14	2001-06-19	Paul C Wilhelmsen	Tablet giving rapid release of nicotine for transmucosal administration
BR0012787A (pt)	1999-07-28	2002-07-30	Univ Leland Stanford Junior	Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora
US7838539B2 (en) *	1999-07-28	2010-11-23	The Board Of Trustees Of The Leland Stanford Junior University	Nicotine receptor agonists in stem cell and progenitor cell recruitment
WO2001015671A2 (fr)	1999-08-30	2001-03-08	Tepha, Inc.	Produits polymeres jetables dans les toilettes
US6905016B2 (en) *	2000-03-14	2005-06-14	Noven Pharmaceuticals, Inc.	Packaging system for transdermal drug delivery systems
KR100337161B1 (ko) *	2000-04-10	2002-05-18	서경배	폴리우레탄 및 폴리에테르를 함유하는 약물 전달용 필름형성제 및 이를 함유하는 경피 투여형 제제
US7658942B2 (en) *	2000-04-12	2010-02-09	The Procter & Gamble Company	Cosmetic devices
US7179483B2 (en) *	2000-04-26	2007-02-20	Watson Pharmaceuticals, Inc.	Compositions and methods for transdermal oxybutynin therapy
DE10053376A1 (de) *	2000-10-27	2002-05-23	Lohmann Therapie Syst Lts	Haltevorrichtung für flächenförmige wirkstoffhaltige Systeme und ihre Verwendung zur Bestimmung der Wirkstofffreisetzung
DE10056014A1 (de) *	2000-11-11	2002-05-16	Beiersdorf Ag	Mehrschichtige Trägerkonstruktion für wirkstofhaltige Pflastersyteme
US6682757B1 (en)	2000-11-16	2004-01-27	Euro-Celtique, S.A.	Titratable dosage transdermal delivery system
DE10110391A1 (de) *	2001-03-03	2002-09-26	Lohmann Therapie Syst Lts	Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff
SE521512C2 (sv)	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
IL160928A0 (en) *	2001-10-19	2004-08-31	Maxim Pharm Inc	Use of histamine to treat liver disease
JP2005508366A (ja) *	2001-11-06	2005-03-31	マキシムファーマシューティカルス，インコーポレイテッド	感染性疾患の治療用組成物
MXPA04003807A (es) *	2001-11-30	2004-07-30	Pfizer Prod Inc	Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
JP2003192773A (ja) *	2001-12-26	2003-07-09	Mitsui Chemicals Inc	生体吸収性ポリヒドロキシカルボン酸及びその製造法
JP2006501224A (ja) *	2002-08-22	2006-01-12	ニュートリション２１、インコーポレイテッド	アルギニンケイ酸塩イノシトール複合体およびその使用
US20040086551A1 (en) *	2002-10-30	2004-05-06	Miller Kenneth J.	Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
DK1803443T3 (en)	2002-12-20	2019-02-25	Niconovum Ab	Nicotine-containing particulate material with a crystalline cellulose
NZ541365A (en) *	2002-12-27	2009-09-25	Diobex Inc	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) *	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20040258742A1 (en) *	2003-04-11	2004-12-23	Van Osdol William Woodson	Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
OA13160A (en)	2003-04-24	2006-12-13	Univ Vanderbilt	Compositions and methods for controlling insects.
US7622269B2 (en)	2004-03-19	2009-11-24	Tyratech, Inc.	Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
PT1638615E (pt)	2003-05-08	2015-02-04	Tepha Inc	Fibras e tecidos médicos de polihidroxialcanoato
JP2007528853A (ja) *	2003-07-08	2007-10-18	テファ，インコーポレイテッド	徐放性薬物送達のためのポリ−４−ヒドロキシブチレートマトリックス
US8524272B2 (en)	2003-08-15	2013-09-03	Mylan Technologies, Inc.	Transdermal patch incorporating active agent migration barrier layer
EP1663017A1 (fr) *	2003-08-22	2006-06-07	Tepha, Inc.	Dispositifs de regeneration nerveuse a base de polyhydroxyalkanoate
US20070212402A1 (en) *	2003-12-05	2007-09-13	Rooven Qainton V	Patch
US20050171192A1 (en) *	2003-12-11	2005-08-04	Gehlsen Kurt R.	Use of histamine to treat bone disease
US7105263B2 (en) *	2003-12-30	2006-09-12	Samsung Electronics Company	Dry toner comprising encapsulated pigment, methods and uses
NZ549939A (en) *	2004-03-19	2009-12-24	Mcneil Ab	Means for transdermal administration of nicotine
WO2006009975A2 (fr) *	2004-06-22	2006-01-26	Maxim Pharmaceuticals, Inc.	Utilisation d'histamine et de composes associes pour traiter des troubles de la fonction musculaire
US20060008432A1 (en) *	2004-07-07	2006-01-12	Sebastiano Scarampi	Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
ES2395464T3 (es) *	2004-08-03	2013-02-12	Tepha, Inc.	Suturas de polihidroxialcanoato no rizadas
AU2005316295B2 (en)	2004-12-17	2012-03-22	Alan B. Cash	Method for extending lifespan and delaying the onset of age-related disease
US20060177513A1 (en) *	2005-01-28	2006-08-10	Tepha, Inc.	Embolization using poly-4-hydroxybutyrate particles
US20060264455A1 (en)	2005-05-23	2006-11-23	Schachter Steven C	Use of huperzine for disorders
US20070098772A1 (en) *	2005-09-23	2007-05-03	Westcott Tyler D	Transdermal norelgestromin delivery system
EP2308480B1 (fr)	2005-09-23	2014-08-13	ALZA Corporation	Formulation de polyacrylate hautement chargée en activateur pour des applications transdermiques
US7888422B2 (en) *	2005-11-09	2011-02-15	Mylan Technologies Inc.	Long-wearing removable pressure sensitive adhesive
US20090246264A1 (en) *	2005-12-08	2009-10-01	Fertin Pharma	Transdermal Tobacco Alkaloid Patch
WO2007065428A1 (fr) *	2005-12-08	2007-06-14	Fertin Pharma	Timbre transdermique d'alcaloide du tabac a faible resistance a la flexion
CA2646942C (fr)	2006-03-16	2014-07-29	Modoral Brands Inc.	Composition amelioree de tabac a priser
JP5000910B2 (ja) *	2006-03-29	2012-08-15	リンテック株式会社	貼付剤及びその製造方法
US20070259930A1 (en) *	2006-04-10	2007-11-08	Knopp Neurosciences, Inc.	Compositions and methods of using r(+) pramipexole
US8518926B2 (en) *	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) *	2006-05-16	2009-02-27	크놉 뉴로사이언시스 인코포레이티드	Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US20080145462A1 (en)	2006-06-27	2008-06-19	Essam Enan	Compositions and methods for treating parasitic infections
US20110150766A1 (en) *	2006-07-07	2011-06-23	Royds Robert B	Transdermal patch with fatal overdose protection
US20080008747A1 (en) *	2006-07-07	2008-01-10	Royds Robert B	Transdermal patch
US8685471B2 (en)	2006-07-17	2014-04-01	Tyratech, Inc.	Compositions and methods for controlling insects
US7943683B2 (en) *	2006-12-01	2011-05-17	Tepha, Inc.	Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP5537951B2 (ja)	2006-12-21	2014-07-02	トラスティーズ・オブ・タフツ・カレッジ	癌及びグルコース代謝障害の治療に用いる合成親油性イノシトールグリカン
CN101715443A (zh)	2007-03-14	2010-05-26	诺普神经科学股份有限公司	手性纯化的取代的苯并噻唑二胺的合成
AU2007353989A1 (en) *	2007-05-31	2008-12-04	Fertin Pharma A/S	Transdermal tobacco alkaloid reservoir patch
DK2158908T3 (da) *	2007-06-21	2013-07-29	Fujimoto Co Ltd	Sammensætning til transdermal administrering
WO2009003466A1 (fr)	2007-07-04	2009-01-08	Acino Ag	Système à réservoir muni d'une membrane fermée
US9017301B2 (en) *	2007-09-04	2015-04-28	Mylan Technologies, Inc.	Transdermal drug delivery systems comprising a coated release liner
ATE551977T1 (de) *	2008-02-28	2012-04-15	Steffen Barth	Pflaster
CN102036668A (zh) *	2008-03-19	2011-04-27	蒂拉德克公司	有害生物防治组合物和方法
DE102008015101A1 (de)	2008-03-19	2009-09-24	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Kauzusammensetzung und deren Verwendung
WO2010005850A1 (fr)	2008-07-08	2010-01-14	The J. David Gladstone Institutes	Procédés et compositions de modulation de l’angiogenèse
US20110190356A1 (en) *	2008-08-19	2011-08-04	Knopp Neurosciences Inc.	Compositions and Methods of Using (R)- Pramipexole
US20110224245A1 (en) *	2008-09-04	2011-09-15	President And Fellows Of Harvard College	Treatment Of Neurological Disorders Using Huperzine
GB0817486D0 (en) *	2008-09-24	2008-10-29	Smith & Nephew	Delivery system
US20100221313A1 (en) *	2008-12-01	2010-09-02	Innovative Pharmaceuticals, Llc	Transdermal reservoir patch
CN102802418A (zh) *	2009-06-19	2012-11-28	诺普神经科学股份有限公司	用于治疗肌萎缩性侧索硬化的组合物和方法
JP6527305B2 (ja)	2011-01-10	2019-06-05	インヴィオン，インコーポレイテッド	禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用
WO2013096816A1 (fr)	2011-12-22	2013-06-27	Biogen Idec Ma Inc.	Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US20140271923A1 (en)	2013-03-14	2014-09-18	Christopher Brian Reid	Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2014188329A2 (fr)	2013-05-20	2014-11-27	Mylan, Inc.	Système thérapeutique transdermique pour dosage à libération prolongée de pramipexole dans le traitement de troubles neurologiques
ES3043076T3 (en)	2013-07-12	2025-11-24	Areteia Therapeutics Inc	Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
WO2015023786A1 (fr)	2013-08-13	2015-02-19	Knopp Biosciences Llc	Compositions et méthodes de traitement de troubles des cellules plasmatiques et de troubles prolymphocytaires à cellules b
ES2871556T3 (es)	2013-08-13	2021-10-29	Knopp Biosciences Llc	Composiciones y métodos para el tratamiento de la urticaria crónica
DE102014000200A1 (de) *	2014-01-03	2015-07-09	Michael Horstmann	Transdermales Therapeutisches System
US10500303B2 (en)	2014-08-15	2019-12-10	Tepha, Inc.	Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
EP3230500B1 (fr)	2014-12-11	2025-06-18	Tepha, Inc.	Méthodes d'orientation de fil multifilament et de monofilaments de poly-4-hydroxybutyrate et ses copolymères
US10626521B2 (en)	2014-12-11	2020-04-21	Tepha, Inc.	Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
US11191735B2 (en)	2015-03-13	2021-12-07	Nutrition 21, Llc	Arginine silicate for periodontal disease
US20170135969A1 (en)	2015-11-12	2017-05-18	Jds Therapeutics, Llc	Topical arginine-silicate-inositol for wound healing
EP3397081A4 (fr) *	2015-12-30	2019-08-28	Next Generation Labs, LLC	Produits de substitution de la nicotine comprenant une nicotine de synthèse
CN109890384A (zh)	2016-09-01	2019-06-14	Jds治疗有限公司	生物素镁组合物和使用方法
ES2950096T3 (es)	2016-09-22	2023-10-05	Alan B Cash	Método para aliviar los síntomas del síndrome premenstrual
CA3118583C (fr)	2018-11-02	2024-05-14	Nutrition 21, Llc	Compositions contenant des complexes de silicate d'arginine stabilises par inositol et inositol pour ameliorer la fonction cognitive chez des joueurs de jeu video
IL294021A (en)	2019-12-16	2022-08-01	Nutrition 21 Llc	Methods of production of arginine-silicate complexes
DE102020112143B4 (de)	2020-05-05	2022-03-17	Lts Lohmann Therapie-Systeme Ag	Nicotin - Corona
CA3204220A1 (fr)	2021-01-14	2022-07-21	Alan B. Cash	Traitement de la fatigue pathologique a l'aide d'oxaloacetate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) *	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3598122A (en) *	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3731683A (en) *	1971-06-04	1973-05-08	Alza Corp	Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) *	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3742951A (en) *	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
US4624665A (en) *	1984-10-01	1986-11-25	Biotek, Inc.	Method of transdermal drug delivery
US4687481A (en) *	1984-10-01	1987-08-18	Biotek, Inc.	Transdermal drug delivery system
DE3438284A1 (de) *	1984-10-16	1985-03-07	Hans-Harald von 2400 Lübeck Tilly	Nikotinhaltiges depotpflaster
US4638043A (en) *	1984-11-13	1987-01-20	Thermedics, Inc.	Drug release system
US4597961A (en) *	1985-01-23	1986-07-01	Etscorn Frank T	Transcutaneous application of nicotine
US4706676A (en) *	1985-02-11	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Dermal substance collection device
JPS61251619A (ja) *	1985-04-30	1986-11-08	Nitto Electric Ind Co Ltd	ニコチン含有テ−プ製剤
US4715387A (en) *	1985-08-23	1987-12-29	The Regents Of The Univ. Of California	Aerosol for use in the reduction of tobacco smoking
US4627429A (en) *	1986-02-28	1986-12-09	American Home Products Corporation	Storage-stable transdermal adhesive patch
DE3629304A1 (de) *	1986-08-28	1988-03-24	Lohmann Gmbh & Co Kg	Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
DE3786998D1 (de) *	1986-11-20	1993-09-16	Ciba Geigy Ag	Benutzer-aktivierte therapeutische systeme.
US4839174A (en) *	1987-10-05	1989-06-13	Pharmetrix Corporation	Novel transdermal nicotine patch
PT90820B (pt) *	1988-06-14	1995-05-31	Alza Corp	Dispositivo de libertacao transdermica sub-saturado

1988
- 1988-10-28 US US07/264,397 patent/US4943435A/en not_active Expired - Lifetime
1989
- 1989-09-01 DK DK198904341A patent/DK175328B1/da not_active IP Right Cessation
- 1989-09-04 NZ NZ230554A patent/NZ230554A/xx unknown
- 1989-09-04 AU AU41057/89A patent/AU635714B2/en not_active Expired
- 1989-09-05 EP EP98116736A patent/EP0916339B1/fr not_active Expired - Lifetime
- 1989-09-05 CA CA000610299A patent/CA1338009C/fr not_active Expired - Lifetime
- 1989-09-05 AT AT98116736T patent/ATE292968T1/de not_active IP Right Cessation
- 1989-09-05 NO NO893570A patent/NO301216B1/no unknown
- 1989-09-05 DE DE68928952T patent/DE68928952T2/de not_active Expired - Lifetime
- 1989-09-05 AT AT89308978T patent/ATE177651T1/de not_active IP Right Cessation
- 1989-09-05 EP EP89308978A patent/EP0366240B1/fr not_active Expired - Lifetime
- 1989-09-05 DE DE68929533T patent/DE68929533T2/de not_active Expired - Lifetime
- 1989-09-05 ES ES89308978T patent/ES2129387T3/es not_active Expired - Lifetime
- 1989-09-05 ES ES98116736T patent/ES2241083T3/es not_active Expired - Lifetime
- 1989-09-07 MX MX017462A patent/MX165947B/es unknown
- 1989-09-28 JP JP25369089A patent/JP3359630B2/ja not_active Expired - Lifetime
1999
- 1999-04-23 GR GR990401118T patent/GR3030041T3/el unknown

Also Published As

Publication number	Publication date
JP3359630B2 (ja)	2002-12-24
ES2129387T3 (es)	1999-06-16
AU635714B2 (en)	1993-04-01
EP0366240A1 (fr)	1990-05-02
CA1338009C (fr)	1996-01-30
ATE292968T1 (de)	2005-04-15
EP0916339B1 (fr)	2005-04-13
NZ230554A (en)	1991-02-26
JPH02174714A (ja)	1990-07-06
DK434189A (da)	1990-04-29
US4943435A (en)	1990-07-24
DE68929533D1 (de)	2005-05-19
DK175328B1 (da)	2004-08-23
DE68928952D1 (de)	1999-04-22
EP0366240B1 (fr)	1999-03-17
AU4105789A (en)	1990-05-03
EP0916339A1 (fr)	1999-05-19
NO893570D0 (no)	1989-09-05
ATE177651T1 (de)	1999-04-15
DE68928952T2 (de)	1999-08-26
MX165947B (es)	1992-12-09
NO893570L (no)	1990-04-30
DE68929533T2 (de)	2006-03-09
ES2241083T3 (es)	2005-10-16
DK434189D0 (da)	1989-09-01
GR3030041T3 (en)	1999-07-30

Publication	Publication Date	Title
US4943435A (en)	1990-07-24	Prolonged activity nicotine patch
US4839174A (en)	1989-06-13	Novel transdermal nicotine patch
US5135753A (en)	1992-08-04	Method and therapeutic system for smoking cessation
US4849224A (en)	1989-07-18	Device for administering an active agent to the skin or mucosa
EP0608357B1 (fr)	1997-12-29	Dispositif permettant l'administration transcutanee d'un medicament avec une variation temporelle regulee du flux a travers la peau
AU695170B2 (en)	1998-08-06	Transdermal delivery system with adhesive overlay and peel seal disc
US5271940A (en)	1993-12-21	Transdermal delivery device having delayed onset
CA1262098A (fr)	1989-10-03	Systeme de dispensation transcutanee de mitroglycerine a flux abondant
FR2581314A1 (fr)	1986-11-07	Dispositif medical pour l'administration transdermique de medicaments fortement ionises insolubles dans les corps gras
EP0600023A1 (fr)	1994-06-08	Dispositif de liberation d'un medicament transdermique utilisant une membrane a micropores protegee par des membranes dans le but de produire un effet retard
FR2567761A1 (fr)	1986-01-24	Dispositif d'apport transdermique pour l'administration de fentanyl
AU614728B2 (en)	1991-09-12	User-activated transdermal therapeutic systems
AU650851B2 (en)	1994-07-07	Transdermal delivery device having delayed onset
SI9300387A (en)	1994-03-31	Transdermale therapeutic system containing active 17-beta estradiol (dry acid)
JP3172395B2 (ja)	2001-06-04	経皮薬剤放出デバイス
EP0262753A1 (fr)	1988-04-06	Système d'administration transdermale de scopolamine
WO1992009252A1 (fr)	1992-06-11	Procede et dispositif destines a traiter le tabagisme
CA1338700C (fr)	1996-11-12	Dispositif d'administration transdermique sous-sature
HK1009583B (en)	2000-07-28	Device for treating tobacco addiction